A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease - Trial PHRR200909-002920
Access comprehensive clinical trial information for PHRR200909-002920 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novartis Healthcare Philippines, Inc. and is currently Terminated. The study focuses on Cardiovascular Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR200909-002920
Phase 3
Terminated
Trial Details
Philippine Health Research Registry • PHRR200909-002920
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
Study Focus
Interventional
Sponsor & Location
Novartis Healthcare Philippines, Inc.
Novartis Pharma Services AG
Australia;China;Denmark;Germany;Hong;Kong;India;Japan;Malaysia;Poland;Singapore;United;States
Timeline & Enrollment
Phase 3
Jun 26, 2019
Jul 30, 2023
ICD-10 Classifications
Cardiovascular disease, unspecified
Hypertensive heart disease
Heart disease, unspecified
Atherosclerotic cardiovascular disease, so described
Atherosclerotic heart disease
Data Source
Philippine Health Research Registry
PHRR200909-002920
Non-Device Trial